Protocol Ledger

NCT06963827 · Phase III · RECRUITING

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

Interventional Phase III clinical trial protocol NCT06963827 sponsored by Takeda in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-15 Enrollment: 347 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06963827
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)347 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06963827
Protocol FieldVerified Registry Value
NCT IdentifierNCT06963827
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment347 participants (ESTIMATED)
Registered Start Date2025-07-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06963827
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI